MétaCan
Menu
Back to cohort
Record W4386529632 · doi:10.1016/j.jaci.2023.08.030

Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials

2023· review· en· W4386529632 on OpenAlexaff
Derek K. Chu, A. Chu, Daniel Rayner, Gordon Guyatt, Juan José Yepes-Núñez, Luis G. Gómez-Escobar, Lucía C. Pérez-Herrera, Juan Pablo Díaz Martinez, Romina Brignardello‐Petersen, Behnam Sadeghirad, Melanie Wong, Renata Ceccacci, Irene X. Zhao, John Basmaji, Margaret MacDonald, Xiajing Chu, Nazmul Islam, Ya Gao, Ariel Izcovich, Rachel N. Asiniwasis, Mark Boguniewicz, Anna De Benedetto, Korey Capozza, Lina Chen, Kathy Ellison, Winfred Frazier, Matthew Greenhawt, Joey Huynh, Jennifer LeBovidge, Peter Lio, Stephen A. Martin, Monica O’Brien, Peck Y. Ong, Jonathan I. Silverberg, Jonathan M. Spergel, Wendy Smith Begolka, Julie Wang, Kathryn E. Wheeler, Donna D. Gardner, Lynda C. Schneider

Bibliographic record

VenueJournal of Allergy and Clinical Immunology · 2023
Typereview
Languageen
FieldMedicine
TopicDermatology and Skin Diseases
Canadian institutionsUniversity of SaskatchewanHamilton Health SciencesWestern UniversityMcMaster UniversitySt. Joseph’s Healthcare HamiltonImpact
Fundersnot available
KeywordsAtopic dermatitisDermatologyMedicineRandomized controlled trialMeta-analysisSurgeryInternal medicine

Abstract

fetched live from OpenAlex

BACKGROUND: Atopic dermatitis (AD) is a common skin condition with multiple topical treatment options, but uncertain comparative effects. OBJECTIVE: We sought to systematically synthesize the benefits and harms of AD prescription topical treatments. METHODS: For the 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma, and Immunology Joint Task Force on Practice Parameters AD guidelines, we searched MEDLINE, EMBASE, CENTRAL, CINAHL, LILACS, ICTRP, and GREAT databases to September 5, 2022, for randomized trials addressing AD topical treatments. Paired reviewers independently screened records, extracted data, and assessed risk of bias. Random-effects network meta-analyses addressed AD severity, itch, sleep, AD-related quality of life, flares, and harms. The Grading of Recommendations Assessment, Development and Evaluation approach informed certainty of evidence ratings. We classified topical corticosteroids (TCS) using 7 groups-group 1 being most potent. This review is registered in the Open Science Framework (https://osf.io/q5m6s). RESULTS: The 219 included trials (43,123 patients) evaluated 68 interventions. With high-certainty evidence, pimecrolimus improved 6 of 7 outcomes-among the best for 2; high-dose tacrolimus (0.1%) improved 5-among the best for 2; low-dose tacrolimus (0.03%) improved 5-among the best for 1. With moderate- to high-certainty evidence, group 5 TCS improved 6-among the best for 3; group 4 TCS and delgocitinib improved 4-among the best for 2; ruxolitinib improved 4-among the best for 1; group 1 TCS improved 3-among the best for 2. These interventions did not increase harm. Crisaborole and difamilast were intermediately effective, but with uncertain harm. Topical antibiotics alone or in combination may be among the least effective. To maintain AD control, group 5 TCS were among the most effective, followed by tacrolimus and pimecrolimus. CONCLUSIONS: For individuals with AD, pimecrolimus, tacrolimus, and moderate-potency TCS are among the most effective in improving and maintaining multiple AD outcomes. Topical antibiotics may be among the least effective.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.006
metaresearch head score (Gemma)0.015
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (broad)
Consensus categoriesMeta-epidemiology (broad)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.123
Threshold uncertainty score0.996

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0060.015
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0440.014
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.251
GPT teacher head0.477
Teacher spread0.227 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations101
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Allergy and Clinical ImmunologySame topicDermatology and Skin DiseasesFrench-language works237,207